Sudhir Srivastava

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Proteomic maps of the cancer-associated infectious agents
    Sudhir Srivastava
    Cancer Biomarkers Research Group, Analytical Epidemiology Branch, Organ System Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Proteome Res 4:1171-80. 2005
  2. ncbi Molecular screening of cancer: the future is here
    Sudhir Srivastava
    Cancer Biomarkers Research Group, National Cancer Institute, Rockville, Maryland 20852, USA
    Mol Diagn Ther 10:221-30. 2006
  3. ncbi Multiple strand displacement amplification of mitochondrial DNA from clinical samples
    Samantha Maragh
    Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
    BMC Med Genet 9:7. 2008
  4. ncbi Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells
    Yan Xiao
    Chemical Science and Technology Laboratory, National Institute of Standards and Technology NIST, Gaithersburg, MD, USA
    BMC Cancer 9:351. 2009
  5. ncbi Performance of mitochondrial DNA mutations detecting early stage cancer
    John P Jakupciak
    Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
    BMC Cancer 8:285. 2008
  6. ncbi Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0
    John P Jakupciak
    Cipher Systems, Crofton, USA
    BMC Cancer 8:95. 2008
  7. ncbi Proteomics in the forefront of cancer biomarker discovery
    Sudhir Srivastava
    Cancer Biomarkers Research Group of National Cancer Institute, EPN 3142, 6130 Executive Boulevard, Rockville, MD 20852, USA
    J Proteome Res 4:1098-103. 2005
  8. ncbi Challenges for biomarkers in cancer detection
    Paul D Wagner
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-7346, USA
    Ann N Y Acad Sci 1022:9-16. 2004
  9. ncbi Molecular diagnostics: a new frontier in cancer prevention
    Paul D Wagner
    Cancer Biomarkers Research Group, National Cancer Institute, Bethesda, MD 20892, USA
    Expert Rev Mol Diagn 4:503-11. 2004
  10. ncbi Epigenetics and cancer
    Mukesh Verma
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892 7324, USA
    Crit Rev Clin Lab Sci 41:585-607. 2004

Detail Information

Publications59

  1. ncbi Proteomic maps of the cancer-associated infectious agents
    Sudhir Srivastava
    Cancer Biomarkers Research Group, Analytical Epidemiology Branch, Organ System Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Proteome Res 4:1171-80. 2005
    ..Herein, we discuss the current technologies and challenges in the field, and application of protein signatures in cancer detection and prevention...
  2. ncbi Molecular screening of cancer: the future is here
    Sudhir Srivastava
    Cancer Biomarkers Research Group, National Cancer Institute, Rockville, Maryland 20852, USA
    Mol Diagn Ther 10:221-30. 2006
    ....
  3. ncbi Multiple strand displacement amplification of mitochondrial DNA from clinical samples
    Samantha Maragh
    Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
    BMC Med Genet 9:7. 2008
    ..We applied the method to a small group of cancer cases and controls and demonstrated that WGA is capable of increasing the yield of starting DNA material with identical genetic sequence...
  4. ncbi Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells
    Yan Xiao
    Chemical Science and Technology Laboratory, National Institute of Standards and Technology NIST, Gaithersburg, MD, USA
    BMC Cancer 9:351. 2009
    ....
  5. ncbi Performance of mitochondrial DNA mutations detecting early stage cancer
    John P Jakupciak
    Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
    BMC Cancer 8:285. 2008
    ..The detection of mtDNA mutations in body fluids using resequencing microarrays, which are more sensitive than other sequencing methods, could provide a strategy to measure mutation loads in remote anatomical sites...
  6. ncbi Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0
    John P Jakupciak
    Cipher Systems, Crofton, USA
    BMC Cancer 8:95. 2008
    ..0 (MCv2), and 4) assessing the somatic mtDNA mutation rate in benign breast diseases as a potential tool for monitoring early somatic mutations associated with breast cancer...
  7. ncbi Proteomics in the forefront of cancer biomarker discovery
    Sudhir Srivastava
    Cancer Biomarkers Research Group of National Cancer Institute, EPN 3142, 6130 Executive Boulevard, Rockville, MD 20852, USA
    J Proteome Res 4:1098-103. 2005
  8. ncbi Challenges for biomarkers in cancer detection
    Paul D Wagner
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-7346, USA
    Ann N Y Acad Sci 1022:9-16. 2004
    ..Recent technological advances have helped develop noninvasive, sensitive, and specific biomarkers to detect cancer at early stages of the disease...
  9. ncbi Molecular diagnostics: a new frontier in cancer prevention
    Paul D Wagner
    Cancer Biomarkers Research Group, National Cancer Institute, Bethesda, MD 20892, USA
    Expert Rev Mol Diagn 4:503-11. 2004
    ..Thus, there remains a critical need for new biomarkers for use in early detection and for assay methods that allow the translation of these biomarkers from the laboratory to the clinic...
  10. ncbi Epigenetics and cancer
    Mukesh Verma
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892 7324, USA
    Crit Rev Clin Lab Sci 41:585-607. 2004
    ..Changes in gene expression due to epigenetic regulation can be reversed by chemicals, and this approach opens up a novel approach in cancer prevention and treatment...
  11. ncbi Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools
    Jacob Kagan
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 67:4545-9. 2007
    ....
  12. ncbi Biomarkers in molecular medicine: cancer detection and diagnosis
    Padma Maruvada
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-7346, USA
    Biotechniques . 2005
    ..These biomarkers will be used either as stand-alone tests or to complement existing imaging methods...
  13. ncbi Mitochondria as a target for early detection and diagnosis of cancer
    Jacob Kagan
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland 20852, USA
    Crit Rev Clin Lab Sci 42:453-72. 2005
    ....
  14. ncbi Proteomics for cancer biomarker discovery
    Pothur R Srinivas
    Division of Cancer Prevention, National Cancer Institute, Rockville, MD 20852, USA
    Clin Chem 48:1160-9. 2002
    ..Finally, the review touches on the efforts of the Early Detection Research Network at the National Cancer Institute in promoting biomarker discovery for translation at the clinical level...
  15. ncbi Biomarkers for cancer diagnosis: implications for nutritional research
    Padma Maruvada
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
    J Nutr 134:1640S-1645S; discussion 1664S-1666S, 1667S-1672S. 2004
    ..Biomarkers of dietary intake or metabolism, therefore, could have potential application in study designs for establishing a causal relationship between diet and disease...
  16. ncbi New cancer biomarkers deriving from NCI early detection research
    Mukesh Verma
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institute of Health, 6130 Executive Boulevard, EPN-3142, Rockville, MD 20852-7346, USA
    Recent Results Cancer Res 163:72-84; discussion 264-6. 2003
    ..The network's serious determined efforts in linking discovery to process development, resulting in early detection tests and clinical assessment, are also discussed...
  17. ncbi Markers for early detection of cancer: statistical guidelines for nested case-control studies
    Stuart G Baker
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
    BMC Med Res Methodol 2:4. 2002
    ..This has spurred nested case-control studies that involve testing some specimens for various markers that might predict cancer. Until now there has been little guidance in statistical design and analysis of these studies...
  18. ncbi Biomarkers in oncology research and treatment: early detection research network: a collaborative approach
    Victoria Moncada
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Biomark Med 2:181-95. 2008
    ....
  19. ncbi A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer
    Claire S Zhu
    Division of Cancer Prevention, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 7346, USA
    Cancer Prev Res (Phila) 4:375-83. 2011
    ..Thus, biomarker panels discovered in diagnostic samples may not validate in prediagnostic samples; utilizing prediagnostic samples for discovery may be helpful in developing validated early detection panels...
  20. ncbi Workshop on imaging science development for cancer prevention and preemption
    Gary J Kelloff
    NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
    Cancer Biomark 3:1-33. 2007
    ..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer...
  21. ncbi New paradigms in translational science research in cancer biomarkers
    Paul D Wagner
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, Rockville, MD 20852, USA
    Transl Res 159:343-53. 2012
    ..In this article, we provide our perspective on the relatively slow pace of cancer biomarker translation, especially those for early detection and screening...
  22. ncbi Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics
    Karl E Krueger
    Cancer Biomarkers Research Group, Division of Cancer Prevention, NCI, National Institutes of Health, Bethesda, Maryland 20892-7362, USA
    Mol Cell Proteomics 5:1799-810. 2006
  23. ncbi Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection
    Padma Maruvada
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD 20892-7346, USA
    Cancer Epidemiol Biomarkers Prev 15:1078-82. 2006
    ..The current commentary describes various aspects of statistical considerations and study designs for cancer biomarker validation discussed in this workshop...
  24. ncbi Biomarkers in cancer screening: a public health perspective
    Sudhir Srivastava
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
    J Nutr 132:2471S-2475S. 2002
    ..These discoveries will lead to early clinical validation of tests with improved accuracy and reliability...
  25. ncbi Strategic approach to validating methylated genes as biomarkers for breast cancer
    Wendy Wang
    Cancer Biomarkers Research Group, Division of Cancer Prevention, U S National Cancer Institute, Rockville, MD 20852, USA
    Cancer Prev Res (Phila) 3:16-24. 2010
    ..This commentary summarizes their discussions and recommendations and the rationale for initiating specific projects to validate DNA methylation biomarkers of breast cancer...
  26. ncbi The promise of biomarkers in cancer screening and detection
    Robert S Negm
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD 20852, USA
    Trends Mol Med 8:288-93. 2002
    ..Here, we discuss examples of recent advances and limitations in cancer biomarker identification and validation, and the implications for cancer prevention...
  27. ncbi AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development
    Samir N Khleif
    National Cancer Institute, Raritan, New Jersey, USA
    Clin Cancer Res 16:3299-318. 2010
    ....
  28. ncbi Proteomic analysis of cancer-cell mitochondria
    Mukesh Verma
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 3:789-95. 2003
    ....
  29. ncbi The promise of biomarkers in colorectal cancer detection
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd-EPN 2143, Rockville, MD 20852, USA
    Dis Markers 20:87-96. 2004
  30. ncbi Noncoding RNAs in molecular characterization of cancer preneoplasia
    Wendy Wang
    Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institute of Health CBRG DCP NCI NIH, 6130 Executive Boulevard, MD, USA
    Cancer Biomark 9:133-40. 2010
    ....
  31. ncbi Nutritional links to plausible mechanisms underlying pancreatic cancer: a conference report
    R Jean Hine
    Nutritional Sciences Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-7328, USA
    Pancreas 27:356-66. 2003
    ..The recommendations section suggests gaps in current knowledge and articulates future directions for this area of investigation...
  32. ncbi Epigenetics in cancer: implications for early detection and prevention
    Mukesh Verma
    Cancer Biomarker Research Group, Division of Cancer Prevention, National Cancer Institute, MD 20892 7346, USA
    Lancet Oncol 3:755-63. 2002
    ..The discovery of these basic premises should stimulate much future research on epigenetics...
  33. ncbi Translational Research Working Group developmental pathway for biospecimen-based assessment modalities
    Sudhir Srivastava
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 14:5672-7. 2008
    ..This paper introduces the pathway in the context of prior work and discusses key challenges associated with the biomarker development process in light of the pathway...
  34. ncbi Biomarkers and the genetics of early neoplastic lesions
    Sudhir Srivastava
    National Cancer Institute, National Institutes of Health, Bethesda MD, USA
    Cancer Biomark 9:41-64. 2010
    ....
  35. ncbi Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
    Asad Umar
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Natl Cancer Inst 96:261-8. 2004
    ....
  36. ncbi Nanotechnology in early detection of cancer
    Pothur R Srinivas
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852-7346, USA
    Lab Invest 82:657-62. 2002
  37. ncbi Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens
    Jennifer Maki
    Genesis Genomics, Thunder Bay, Canada
    Am J Clin Pathol 129:57-66. 2008
    ..In a blinded external validation study, the sensitivity and specificity were 83% and 79%, and the area under the ROC curve was 0.87. The 3.4 mtdelta may be useful in defining malignant, benign, and PTM prostate tissues...
  38. ncbi SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer
    Dale McLerran
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Chem 54:53-60. 2008
    ..This report is the 2nd of 2 companion articles describing a validation study of a SELDI-TOF MS approach with IMAC surface sample processing to identify prostatic adenocarcinoma...
  39. ncbi Cancer genetics in the post genomic era
    Sudhir Srivastava
    Curr Mol Med 7:1-2. 2007
  40. ncbi Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility
    O John Semmes
    Department of Microbiology and Molecular Cell Biology, Virginia Prostate Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Clin Chem 51:102-12. 2005
    ..This report describes the first stage of a National Cancer Institute/Early Detection Research Network-sponsored multiinstitutional evaluation and validation of this approach for detection of prostate cancer...
  41. ncbi Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the national institute of standards and technology--National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop, August 18-19,
    Peter E Barker
    NIST-National Cancer Institute Cancer Biomarker Reference Laboratory, NIST Mass Spectrometry Data Center, Analytical Chemistry Division, NIST, Gaithersburg, MD 20899-8311, USA
    Clin Chem 52:1669-74. 2006
    ..This report summarizes the discussion and recommendations for proteomics reference materials...
  42. ncbi Analytical validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells
    John P Jakupciak
    NIST, Biotechnology Division, 100 Bureau Drive, MS 8311, Gaithersburg, MD 20899, USA
    J Mol Diagn 6:157-65. 2004
    ..Using this combination of telomerase activity and hTERT mRNA measurements, the automated system improved efficiency over traditional TRAP/PCR methods...
  43. ncbi Preparation and characterization of candidate reference materials for telomerase assays
    John P Jakupciak
    Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA
    Clin Chem 51:1443-50. 2005
    ..CONCLUSIONS: We have prepared and characterized a candidate reference material that appears to be suitable for use in a wide range of assays of telomerase activity and expression...
  44. ncbi Recent advances in biomarkers for cancer diagnosis and treatment
    Upender Manne
    Department of Pathology, University of Alabama, USA
    Drug Discov Today 10:965-76. 2005
    ..Here, we address issues related to the development of biomarkers, novel technological platforms used for drug development, future technologies and strategies for validating biomarkers for their clinical utility...
  45. ncbi Cancer biomarkers: an emerging means of detecting, diagnosing and treating cancer
    Sudhir Srivastava
    Cancer Biomark 1:1-2. 2005
  46. ncbi Proteomics in diagnostics
    Timothy D Veenstra
    Dis Markers 19:167-8. 2003
  47. ncbi The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology
    William E Grizzle
    University of Alabama at Birmingham, Birmingham, AL, USA
    Urol Oncol 22:337-43. 2004
    ..The methodologies used for this evaluation will prove useful for guiding future biomarker studies in this challenging disease...
  48. ncbi Mitochondrial DNA as a cancer biomarker
    John P Jakupciak
    Biotechnology Division, National Institute of Standards and Technology, 100 Bureau Dr, MS 8311, Gaithersburg, MD 20899, USA
    J Mol Diagn 7:258-67. 2005
    ..Hence, incomplete mitochondrial genome sequencing, designed to scan discrete portions of the genome, misses potentially important sequence variants associated with cancer or other diseases...
  49. ncbi Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women
    Mangalathu S Rajeevan
    Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Int J Cancer 115:114-20. 2005
    ..Cellular proliferation and differentiation pathways affected by HPV should be investigated as biomarkers for cervical cancer screening...
  50. ncbi High-throughput analysis of telomerase by capillary electrophoresis
    Donald H Atha
    Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, MD 20899 8311, USA
    Electrophoresis 24:109-14. 2003
    ..With the appropriate robotic sample handling system, these CE methods would enable performing the telomerase TRAP assay with increased sensitivity, reproducibility and automation over slab-gel methods...
  51. ncbi Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias
    Dale McLerran
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Chem 54:44-52. 2008
    ..Details of this 3-stage process have been described. This report describes the development of the algorithm and results of the blinded test for stage 1...
  52. ncbi Move over proteomics, here comes glycomics
    Sudhir Srivastava
    J Proteome Res 7:1799. 2008
  53. ncbi Immobilization strategies for single-chain antibody microarrays
    Shannon L Seurynck-Servoss
    Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA
    Proteomics 8:2199-210. 2008
    ..Overall, these results suggest that minor modifications of the scFv construct are sufficient to produce reagents that are suitable for use in multiplex assay systems...
  54. ncbi The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop
    Timothy M Block
    Drexel Institute for Biotechnology and Virology Research, Drexel University College of Medicine, Doylestown, PA 18902, USA
    Cancer Biomark 4:19-33. 2008
    ..It is emphasized that only a selected set of biomarkers was considered; thus, this review is not comprehensive and not intended to review all candidate HCC biomarkers...
  55. ncbi Nanotechnology: Emerging Developments and Early Detection of Cancer. A two-day workshop sponsored by the National Cancer Institute and the National Institute of Standards and Technology, August 30-31 2001, on the National Institute of Standards and Techno
    Steven J Zullo
    Chemistry and Life Sciences Division, Advanced Technology Program, National Institute of Standards and Technology, Gaithersburg, MD 20899-4730, USA
    Dis Markers 18:153-8. 2002
    ....
  56. ncbi Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection
    Yan Xiao
    NIST NCI EDRN Cancer Biomarker Reference Laboratory, National Institute of Standards and Technology, Gaithersburg, MD, USA
    Int J Cancer 122:2178-86. 2008
    ....
  57. ncbi Cancer biomarkers. Preface
    Rakesh Dixit
    Merk and Co, Inc
    Cancer Biomark 1:3-4. 2005
  58. ncbi Cancer biomarkers: an emerging means of detecting, diagnosing and treating cancer
    Sudhir Srivastava
    Dis Markers 21:1-2. 2005
  59. ncbi Biomarkers for prostate cancer detection
    Dipen J Parekh
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284 7802, USA
    J Urol 178:2252-9. 2007
    ..New markers that differentiate indolent from aggressive cancers to decrease potential the over treatment of prostate cancer are needed. We reviewed current and potential biomarkers for prostate cancer detection...